Article

Enhanced imatinib uptake through influx transporters and its quantification based on LC-MS/MS in human leukemic cells

2023-05-23

Abstract excerpt

<title>Abstract</title> <p>Chronic myeloid leukemia (CML) is a slowly progressing cancer of the blood cells that originates in the pluripotent hematopoietic stem cells. It is caused by the reciprocal translocation between chromosomes 9 and 22, which results in the formation of a chimeric chromosome referred to as the ‘Philadelphia (Ph) chromosome’. As per GLOBOCAN 2020, leukemia is the tenth most frequently occur...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2c04f739-e25a-518e-b131-22b82d126773
DOI: 10.21203/rs.3.rs-2902713/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Enhanced imatinib uptake through influx transporters and its quantification based on LC-MS/MS in human leukemic cellsDOI 10.21203/rs.3.rs-2902713/v1Read

miR-495-3p Sensitizes BCR::ABL1 Expressing Leukemic cells to Tyrosine Kinase Inhibitors by Targeting Multidrug Resistance 1 Gene including in T315I Mutated cellsSemantic proximity Read

Update on drug transporter proteins in acute myeloid leukemia: Pathological implication and clinical settingSemantic proximity Read

Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically EquivalentSemantic proximity Read

Factors affecting the response to tyrosine kinase inhibitors in chronic myeloid leukaemiaSemantic proximity Read

Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 ActivitySemantic proximity Read

Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagySemantic proximity Read

Biomarkers for BCR-ABL1 as a Potential Therapeutic Option Among Adult Chronic Myeloid Leukaemia Treated With Tyrosine Kinase Inhibitors at Molecular Response in Multi-racial Malaysia: Hsa-mir-181a-5p for Decrement; hsa-mir-182-5p and hsa-mir-26a-5p for Increment.Semantic proximity Read

A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients.Semantic proximity Read

Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target.Semantic proximity Read

De Novo Design of New Inhibitor of Mutated Tyrosine-Kinase for the Myeloid Leukemia Treatment.Semantic proximity Read

Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinibSemantic proximity Read

Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR–CML cell lines?Semantic proximity Read